Mankind Pharma

Mankind Pharma shares slide 3% as Q4 profit declines; details here

Shares of Mankind Pharma dropped over 3 per cent after it posted a 10 per cent fall in consolidated net profit Q4 FY25

Mankind Pharma Q4: Profit drops 10%, revenue up 27% on domestic growth

Strong chronic therapy performance, BSV consolidation drive revenue growth in Q4; net profit declines 10 per cent year-on-year to Rs 425 crore

Stocks to Watch, Feb 27: SBI, Airtel, UltraTech, Nuvama, SpiceJet, IndiGo

Stocks to watch today: SBI has reached a housing loan book of Rs 8 trillion and aims to grow its mortgage book to Rs 10 trillion by March 2027, according to its Chairman, C S Setty

Mankind Pharma sets sights on Novo Nordisk's anti-obesity drug Semaglutide

The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, besides peptides like Glucagon-like peptide-1 (GLP-1)

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Adani Enterprises, Zomato, SpiceJet: 15 stks dip 27% below their QIP price

These 15 companies accounted for 70 per cent of total fund mobilisation of Rs 93,453 crore via QIP route in the past six months, according to PRIME Database.

Mankind Pharma shares crack 6% after Q3 profit drops 16%; know more

Mankind Pharma share slipped 5.61 per cent at Rs 2,487.15 a piece on the BSE in Friday's intraday trade

Mankind Pharma Q3FY25 results: PAT falls 16.5%, revenue rises 24%

Mankind's revenue from operations rose to Rs 3,230 crore in Q3FY25, a 24 per cent Y-o-Y rise from Rs 2,607 crore reported in Q3FY24

Q3 results today: Ultratech, HPCl, Zee among 59 to post earnings on Jan 23

Q3FY25 company results, January 23: Two Adani entities including Adani Energy Solutions and Adani Green Energy will release results for the Oct-Dec quarter today

Mankind Pharma hit with Rs 2.27 crore GST penalty, plans to challenge order

The pharmaceutical giant criticised the order as 'arbitrary and unjustified,' and confirmed plans to challenge the decision

Stocks to Watch, Jan 8, 2025: Tata Steel, Sobha, M&M, REC, SBI, RVNL, CESC

Stocks to Watch, Jan 8, 2025: From Tata Steel to Dr. Reddy's Labs, here is a list of stocks that will remain in focus today

Mankind Pharma inks pact with Innovent for immunotherapy drug in India

Drug used to treat non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin's lymphoma will be priced competitively

Mankind Pharma inks pact with Innovent for immunotherapy drug in India

Mankind Pharma Ltd and Innovent Biologics on Thursday announced a partnership to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region, the companies said in a joint statement. Marketed as TYVYT (sintilimab injection) in China, Sintilimab is co-developed by Innovent and Eli Lilly. "Sintilimab is not approved in India. Early next year, we will be filing for its regulatory approval in India and complete all mandatory regulatory processes, including the conducting of a phase 3 clinical trial by Mankind Pharma for its successful approval in India once we receive the permission from the regulator to conduct such clinical trials," a Mankind Pharma spokesperson said. Under the agreement with Innovent, Mankind Pharma will have exclusive rights to ..

Mankind Pharma dips 5% on profit booking after listing of QIP shares

Mankind Pharma's shares hit a record high of Rs 3,050 on Monday and rallied 13 per cent in past four trading days

Mankind Pharma rises on launching QIP at floor price of Rs 2,616.55

The company launched its qualified institutional placement (QIP) at a floor price of Rs 2,616.55 per share aiming to raise up to Rs 3,000 crore

Mankind Pharma pledges 39.68% in Bharat Serums for Rs 5K crore NCDs

The capital raised through this pledge is expected to support Mankind Pharma's strategic initiatives and growth plans

Mankind Pharma up 6% as PAT rises 29%, margins up 220 bps in Q2FY25

Mankind Pharma declared its September quarter numbers on Tuesday after market hours

Mankind Pharma Q2 results: PAT rises 29% to Rs 659 crore, revenue up 14%

Mankind's revenue from operations rose to Rs 3,077 crore in Q2 FY25, a 13.6 per cent Y-o-Y rise from Rs 2,708 crore reported in Q2 FY24

Mankind Pharma Q2 results: Net profit rises to Rs 653 cr on higher demand

The company, which also makes Manforce condoms and Prega News pregnancy kits, said its consolidated net profit rose to RS 653 crore for the quarter ended Sep 30, a 30% climb from last year